{"id":31060,"date":"2025-07-03T19:02:53","date_gmt":"2025-07-03T19:02:53","guid":{"rendered":"http:\/\/medexperts.pro\/?p=31060"},"modified":"2025-07-03T19:24:57","modified_gmt":"2025-07-03T19:24:57","slug":"drugmakers-notch-a-5-billion-win-in-republicans-policy-bill","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=31060","title":{"rendered":"Drugmakers Notch a $5 Billion Win in Republicans\u2019 Policy Bill"},"content":{"rendered":"
<\/div>\n

More medicines will be spared from Medicare price negotiations, a change that is projected to wipe out billions in savings for the federal government.<\/p>\n

\n
\n
\n

The sweeping Republican policy bill<\/a> that awaits President Trump\u2019s signature on Friday includes a little-noticed victory for the drug industry.<\/p>\n

The legislation allows more medications to be exempt from Medicare\u2019s price negotiation program, which was created to lower the government\u2019s drug spending. Now, manufacturers will be able to keep those prices higher.<\/p>\n

The change will cut into the government\u2019s savings from the negotiation program by nearly $5 billion over a decade, according to<\/a> an estimate by the nonpartisan Congressional Budget Office.<\/p>\n

\u201cThis is essentially giving $5 billion back to the pharmaceutical industry,\u201d said Dr. Benjamin Rome, a health policy researcher at Brigham and Women\u2019s Hospital in Boston. \u201cIt\u2019s done in a way that is designed, on its face, to solve the problem of some misaligned incentives, but I don\u2019t think it solves those problems.\u201d<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

Under existing law, costly drugs are exempt from price negotiations if they are approved to treat a single rare disease \u2014 one that affects fewer than 200,000 Americans. Drugmakers have complained that this policy discourages<\/a> them from running studies and seeking approval to treat a second rare disease, and that it ultimately deprives patients of new treatments.<\/p>\n

In response, the new bill spares drugs that are approved to treat multiple rare diseases. They can still be subject to price negotiations later if they are approved for larger groups of patients, though the change delays those lower prices.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

More medicines will be spared from Medicare price negotiations, a change that is projected to wipe out billions in savings for the federal government.The sweeping Republican policy bill that awaits President Trump\u2019s signature on Friday includes a little-noticed victory for the drug industry.The legislation allows more medications to be exempt from Medicare\u2019s price negotiation program, which was created to lower the government\u2019s drug spending. Now, manufacturers will be able to keep those prices higher.The change will cut into the government\u2019s savings from the negotiation program by nearly $5 billion over a decade, according to an estimate by the nonpartisan Congressional Budget Office.\u201cThis is essentially giving $5 billion back to the pharmaceutical industry,\u201d said Dr. Benjamin Rome, a health policy researcher at Brigham and Women\u2019s Hospital in Boston. \u201cIt\u2019s done in a way that is designed, on its face, to solve the problem of some misaligned incentives, but I don\u2019t think it solves those problems.\u201dUnder existing law, costly drugs are exempt from price negotiations if they are approved to treat a single rare disease \u2014 one that affects fewer than 200,000 Americans. Drugmakers have complained that this policy discourages them from running studies and seeking approval to treat a second rare disease, and that it ultimately deprives patients of new treatments.In response, the new bill spares drugs that are approved to treat multiple rare diseases. They can still be subject to price negotiations later if they are approved for larger groups of patients, though the change delays those lower prices.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":31062,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[],"class_list":["post-31060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/31060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31060"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/31060\/revisions"}],"predecessor-version":[{"id":31063,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/31060\/revisions\/31063"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/31062"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}